|Product Candidate / Program||Drug substance||Indication||Discovery||Pre-clinical||Phase I||Phase II||Phase III / Pivotal||EMA/FDA REVIEW|
|eryaspase (GRASPA® in Europe and Israel)||Asparaginase||ALL||EU|
|AML||EU then EU/US|
|Pancreatic Cancer||EU then EU/US|
eryaspase consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells using our proprietary ERYCAPS platform. L-asparaginase depletes asparagine from circulating blood plasma. Asparagine is a naturally occurring amino acid essential for the survival and proliferation of cells within the body, including cancer cells.
Unlike normal cells, cancer cells often lack the enzymes necessary to produce asparagine internally and therefore must obtain this nutrient from circulating blood. If L-asparaginase can remain in the body long enough to sufficiently deplete circulating asparagine, it can result in the starvation and ultimately the death of cancerous cells.